Abstract
Many functionally important cellular peptides and proteins, including hormones, neuropeptides, and growth factors, are synthesized as inactive precursor polypeptides, which require post-translational proteolytic processing to become biologically active polypeptides. This is achieved by the action of a relatively small number of proteases that belong to a family of seven subtilisin-like proprotein convertases (PCs) including furin. In view of this, this review focuses on the importance of privileged secondary structures and of given amino acid residues around basic cleavage sites in substrate recognition by these endoproteases. In addition to their participation in normal cell functions, PCs are crucial for the initiation and progress of many important diseases. Hence, these proteases constitute potential drug targets in medicine. Accordingly, this review also discusses the approaches used to shed light on the cleavage preference and the substrate specificity of the PCs, a prerequisite to select which PCs are promising drug targets in each disease.
Similar content being viewed by others
References
Myers R (1994) Neuroactive peptides: unique phases in research on mammalian brain over three decades. Peptides 15:367–381
Brakch N, El Abida B, Rholam M (2006) Functional role of β-turn in polypeptide structure and its use as template to design therapeutic agents. Curr Med Chem Cent Nerv Syst Agent 6:163–173
Bennett G, Ballard T, Watson C, Fone K (1997) Effect of neuropeptides on cognitive function. Exp Gerontol 32:451–469
Clynen E, De Loof A, Schoofs L (2003) The use of peptidomics in endocrine research. Gen Comp Endocrinol 132:1–9
Strand F (2003) Neuropeptides: general characteristics and neuropharmaceutical potential in treating CNS disorders. Prog Drug Res 61:1–37
Holmes A, Heilig M, Rupniak N, Steckler T, Griebel G (2003) Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 24:580–588
Shojo H, Kaneko Y (2000) Characterization and expression of oxytocin and the oxytocin receptor. Mol Genet Metab 71:552–558
Gimpl G, Fahrenholz F (2001) The oxytocin receptor system: structure function and regulation. Physiol Rev 81:629–683
Zaoral M (1985) Vasopressin analogues with high and specific antidiuretic activity. Int J Pept Protein Res 25:561–574
Schott P, Hokfelt T, Ogren S (2000) Galanin and spatial learning in the rat. Evidence for a differential role for galanin in subregions of the hippocampal formation. Neuropharmacology 39:1386–1403
Steiner R, Hohmann J, Holmes A, Wrenn C, Cadd G, Juréus A, Clifton D, Luo M, Gutshall M, Ma S, Mufson E, Crawley J (2001) Galanin transgenic mice display cognitive and neurochemical deficits characteristic of Alzheimer’s disease. Proc Natl Acad Sci USA 98:4184–4189
Holsboer F (2003) Corticotropin-releasing hormone modulators and depression. Curr Opin Invest Drugs 4:46–50
Kaschina E, Unger T (2003) Angiotensin AT1/AT2 receptors: regulation, signaling and function. Blood Press 12:70–88
Gendron L, Oligny J, Payet M, Gallo-Payet N (2003) Cyclic AMP-independent involvement of Rap1/B-Raf in the angiotensin II AT2 receptor signaling pathway in NG108-15 Cells. J Biol Chem 278(6):3606–3614
Barker R (1996) Tachykinins, neurotrophism and neurodegenerative diseases: a critical review on the possible role of tachykinins in the aetiology of CNS diseases. Rev Neurosci 7:187–214
Law P, Loh H (1999) Regulation of opioid receptor activities. J Pharmacol Exp Ther 289:607–624
Felig P, Frohman L (1981) Anterior pituitary hormones. In: Endocrinology and metabolism. McGraw-Hill, New York, pp 293–297
Norris D (1997) Tropic hormones of the adenohypophysis. In: Vertebrate endocrinology. Academic, San Diego, pp 137–141
Nakai K (2001) Prediction of in vivo fates of proteins in the era of genomics and proteomics. J Struct Biol 134:103–116
Hubbard S, Beynon R, Thornton J (1998) Assessment of conformational parameters as predictors of limited proteolytic sites in native protein structures. Protein Eng 11:349–359
Shinde U, Inouye M (2000) Intramolecular chaperones: polypeptide extensions that modulate protein folding. Cell Dev Biol 11:35–44
Fontana A, Polverino de Laureto P, De Filippis V, Scaramella E, Zambonin M (2004) Protein structure by limited proteolysis. Acta Biochim Pol 51:299–321
Turk B (2006) Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5:785–799
Steiner D (1998) The proprotein convertases. Curr Opin Chem Biol 2:31–39
Rockwell N, Krysan D, Komiyama T, Fuller R (2002) Precursor processing by Kex2/furin proteases. Chem Rev 102:4525–4548
Seidah N, Prat A (2002) Precursor convertases in the secretory pathway, cytosol and extracellular milieu. Essays Biochem 38:79–94
Fugere M, Day R (2005) Cutting back on proprotein convertases: the latest approaches to pharmacological inhibition. Trends Pharmacol Sci 26:294–301
Bataille D (2007) Pro-protein convertases in intermediary metabolism: islet hormones, brain/gut hormones and integrated physiology. J Mol Med 85:673–684
Hook V, Funkelstein L, Lu D, Bark S, Wegrzyn J, Hwang S-R (2008) Proteases for processing proneuropeptides into peptide neurotransmitters and hormones. Annu Rev Pharmacol Toxicol 48:393–423
Henrich S, Lindberg I, Bode W, Than M (2005) Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity. J Mol Biol 345:211–227
Arolas J, Vendrell J, Aviles F, Fricker L (2007) Metallocarboxypeptidases: emerging drug targets in biomedicine. Curr Pharm Des 13:349–366
Eipper B, Stoffers D, Mains R (1992) The biosynthesis of neuropeptides: peptide alpha-amidation. Annu Rev Neurosci 15:57–85
Wilkinson W (2006) Roles of acetylation and other post-translational modification in melanocortin function and interactions with endorphins. Peptides 27:453–471
Loh Y, Gainer H (1979) The role of glycosylation on the biosynthesis, degradation, and secretion of the ACTH-beta-lipotropin common precursor and its peptide products. FEBS Lett 96:269–272
Cain B, Connolly K, Blum A, Vishnuvardhan D, Marchand J, Beinfeld M (2003) Distribution and colocalization of cholecystokinin with the prohormone convertase enzymes PC1, PC2, and PC5 in rat brain. J Comp Neurol 467:307–325
Patel Y, Galanopoulou A, Rabbani S, Liu J, Ravazzola M, Amherdt M (1997) Somatostatin-14, somatostatin-28, and prosomatostatin1–10 are independently and efficiently processed from prosomatostatin in the constitutive secretory pathway in islet somatostatin tumor cells (1027B2). Mol Cell Endocrinol 131:183–194
Nillni E (2007) Regulation of prohormone convertases in hypothalamic neurons: implications for prothyrotropin-releasing hormone and proopiomelanocortin. Endocrinology 148:4191–4200
Thomas G (2002) Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 3:753–766
Taylor N, Van De Ven W, Creemers J (2003) Curbing activation: proprotein convertases in homeostasis and pathology. FASEB J 7:1215–1227
Scamuffa N, Calvo F, Chrétien M, Seidah N, Khatib A (2006) Proprotein convertases: lessons from knockouts. FASEB J 20:1954–1963
Seidah N, Mayer G, Zaid A, Rousselet E, Nassoury N, Poirier S, Essalmani R, Prat A (2008) The activation and physiological functions of the proprotein convertases. IJBCB 40:1111–1125
Seidah N, Khatib A, Prat A (2006) The proprotein convertases and their implication in sterol and/or lipid metabolism. Biol Chem 387:871–877
Rholam M, Nicolas N, Cohen P (1986) Precursors for peptide hormones share common secondary structures forming features at the proteolytic processing sites. FEBS Lett 207:1–6
Bek E, Berry R (1990) Prohormonal cleavage sites are associated with omega loops. Biochemistry 29:178–183
Monsalve R, Menéndez-Arias L, López-Otin C, Rodriguez R (1990) Beta-turns as structural motifs for the proteolytic processing of seed proteins. FEBS Lett 263:209–212
Rholam M, Brakch N, Germain D, Thomas D, Fahy C, Boussetta H, Boileau G, Cohen P (1995) Role of amino acid sequences flanking dibasic cleavage sites in precursor proteolytic processing. The importance of the first residue C-terminal of the cleavage site. Eur J Biochem 227:707–714
Devi L (1991) Consensus sequence for processing of peptide precursors at monobasic sites. FEBS Lett 280:189–194
Veenstra J (2000) Mono- and dibasic proteolytic cleavage sites in insect neuroendocrine peptide precursors. Arch Insect Biochem Physiol 43:49–63
Hummon A, Hummon N, Corbin R, Li L, Vilim F, Weiss K, Sweedler J (2003) From precursor to final peptides: a statistical sequence-based approach to predicting prohormone processing. J Proteome Res 2:650–656
Duckert P, Brunak S, Blom N (2004) Prediction of proprotein convertase cleavage Sites. Protein Eng Des Sel 17:107–112
Southey B, Rodriguez-Zas S, Sweedler J (2006) Prediction of neuropeptide prohormone cleavages with application to Rfamides. Peptides 27:1087–1098
Amare A, Hummon A, Southey B, Zimmerman T, Rodriguez-Zas S, Sweedler J (2006) Bridging neuropeptidomics and genomics with bioinformatics: prediction of mammalian neuropeptide prohormone processing. J Proteome Res 5:1162–1167
Southey B, Sweedler J, Rodriguez-Zas S (2008) Prediction of neuropeptide cleavage sites in insects. Bioinformatics 24:815–825
Tegge A, Southey B, Southey B (2008) Comparative analysis of neuropeptides cleavage sites in human, mouse, rat and cattle. Mamm Genome 19:106–120
Rholam M, Cohen P (1997) Peptides as tools for studying propeptide and proprotein processing. Anal Chim Acta 352:155–178
Pribic R, van Stokkum I, Chapman D, Haris P, Bloemendal M (1993) Protein secondary structure from Fourier transform infrared and/or circular dichroism. Anal Biochem 214:366–378
Woody R, Dunker A (1996) In: Fasman GD (ed) Circular dichroism and the conformational analysis of biomolecules. Plenum Press, New York, pp 109–157
Paolillo L, Simonetti M, Brakch N, D’Auria G, Saviano M, Dettin M, Rholam M, Scatturin A, Di Bello C, Cohen P (1992) Evidence for the presence of a secondary structure at the dibasic processing site of prohormone: the pro-ocytocin model. EMBO J 11:2399–2405
Falcigno L, Paolillo L, D’Auria G, Saviano M, Simonetti M, Di Bello C (1996) NMR conformational studies on a synthetic peptide reproducing the [1–20] processing domain of the pro-ocytocin-neurophysin precursor. Biopolymers 39:837–848
Velikson B, Cohen P, Rholam M, Rose P, Wang B, Smith J (1998) Structural modeling of the pro-ocytocin-neurophysin precursor. Protein Eng 11:909–916
Rayne R, O’shea M (1993) Structural requirements for processing of pro-adipokinetic hormone I. Eur J Biochem 217:905–911
Weiss A, Franck H, Khait A, Heiney R, Shoelson S, Neuringer L (1990) NMR and photo-CIDNP studies of human proinsulin and prohormone processing intermediates with application to endopeptidase recognition. Biochemistry 29:8389–8401
Brakch N, Rholam M, Boussetta H, Cohen P (1993) Role of beta-turn in proteolytic processing of peptide hormone precursors at dibasic sites. Biochemistry 32:4925–4930
Glandières JM, Hertzog M, Lazar N, Brakch N, Cohen P, Alpert B, Rholam M (2002) Kinetics of precursor cleavage at the dibasic sites. Involvement of peptide dynamics. FEBS Lett 16:75–79
Brakch N, Rholam M, Simonetti M, Cohen P (2000) Favourable side-chain orientation of cleavage site dibasic residues of prohormone in proteolytic processing by prohormone convertase 1/3. Eur J Biochem 267:1626–1632
Rozan L, Krysan D, Rockwell N, Fuller R (2004) Plasticity of extended subsites facilitates divergent substrate recognition by Kex2 and furin. J Biol Chem 279:35656–35663
Bergeron E, Basak A, Decroly E, Seidah N (2003) Processing of α4 integrin by the proprotein convertases: histidine at position P6 regulates cleavage. Biochem J 373:475–484
Lazar N, Brakch N, Panchal M, Fahy C, Rholam M (2007) Reactivity of basic amino acid pairs in prohormone processing: model of pro-ocytocin/neurophysin processing domain. Arch Biochem Biophys 463:231–236
Sillerud L, Larson R (2005) Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction. Curr Protein Pept Sci 6:151–169
Chou K-C (2000) Prediction of tight turns and their types in proteins. Anal Biochem 286:1–16
Fuchs P, Alix A (2005) High accuracy prediction of β-turns and their types using propensities and multiple alignments. Proteins Struct Funct Bioinform 59:828–839
Marcelino A, Gierasch L (2008) Roles of β-turns in protein folding: from peptide models to protein engineering. Biopolymers 89:380–391
Lechan R, Wu P, Jackson I, Wolfe H, Cooperman S, Mandel G, Goodman R (1986) Thyrotropin-releasing hormone precursor: characterization in rat brain. Science 231:159–161
Takahashi H, Teranishi Y, Nakanishi S, Numa S (1981) Isolation and structural organization of the human corticotropin-beta-lipotropin precursor gene. FEBS Lett 135:97–102
Fontès G, Lajoix A, Bergeron F, Cadel S, Prat A, Foulon T, Gross R, Dalle S, Le-Nguyen D, Tribillac F, Bataille D (2005) Miniglucagon (MG)-generating endopeptidase, which processes glucagon into MG, is composed of N-arginine dibasic convertase and aminopeptidase B. Endocrinology 146:702–712
Olias G, Viollet C, Kusserow H, Epelbaum J, Meyerhof W (2004) Regulation and function of somatostatin receptors. J Neurochem 89:1057–1091
Bourdais J, Cohen P (1991) Post-translational proteolytic maturation of prosomatostatin. Cellular and molecular approach. Ann Endocrinol 52:339–347
Puebla L, Mouchantaf R, Sasi R, Khare S, Bennett H, James S, Patel Y (1999) Processing of rat preprocortistatin in mousse AtT-20. J Neurochem 73:1273–1277
Brakch N, Galanopoulou A, Patel Y, Boileau G, Seidah N (1995) Comparative proteolytic processing of rat prosomatostatin by the convertases PC1, PC2, furin, PACE4 and PC5 in constitutive and regulated secretory pathways. FEBS Lett 362:143–146
Chesneau V, Pierotti A, Prat A, Gaudoux F, Foulon T, Cohen P (1994) N-arginine dibasic convertase (NRD convertase): a newcomer to the family of processing endopeptidases. Biochimie 76:234–240
Mouchantaf R, Watt H, Sulea T, Seidah N, Alturaihi H, Patel Y, Kumar U (2004) Prosomatostatin is proteolytically processed at the amino terminal segment by subtilase SKI-1. Regul Pept 120:133–140
Gomez S, Boileau G, Zollinger L, Nault C, Rholam M, Cohen P (1989) Site-specific mutagenesis identifies amino acid residues critical in prohormone processing. EMBO J 8:2911–2916
Brakch N, Boileau G, Simonetti M, Nault C, Joseph-Bravo P, Rholam M, Cohen P (1993) Prosomatostatin processing in Neuro2A cells. Role of beta-turn structure in the vicinity of the Arg–Lys cleavage site. Eur J Biochem 16:39–47
Brakch N, Rholam M (2003) Differential proteolytic processing of prosomatostatin. Curr Top Biochem Res 5:193–207
Brakch N, Rholam M, Nault C, Boileau G, Cohen P (1991) Differential processing of hormone precursor. Independent production of somatostatins 14 and 28 in transfected neuroblastoma 2A cells. FEBS Lett 282:363–367
MacArthur M, Thornton J (1991) Influence of proline residues on protein conformation. J Mol Biol 218:397–412
Vanhoof G, Goossens F, De Meester I, Hendriks D, Scharpe S (1995) Proline motifs in peptides and their biological processing. FASEB J 8:736–744
Munoz V, Serrano L (1994) Elucidating the folding problem of helical peptides using empirical parameters. Nat Struct Biol J 1:399–409
Brakch N, Lazar N, Panchal M, Allemandou F, Boileau G, Cohen P, Rholam M (2002) The somatostatin-28(1–12)-NPAMAP sequence: an essential helical-promoting motif governing prosomatostatin processing at mono- and di-basic sites. Biochemistry 41:1630–1639
Roebroek A, Umans L, Pauli I, Robertson E, van Leuven F, Van de Ven W, Constam D (1998) Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase furin. Development 125:4863–4876
Essalmani R, Hamelin J, Marcinkiewwicz E, Chamberland A, Mbikay M, Chretien C, Seidah N, Prat A (2006) Deletion of the gene encoding proprotein convertase 5/6 causes early embryonic lethality in the mouse. Mol Cell Biol 26:354–361
Mbikay M, Tadros H, Ishida N, Lerner C, De Lamirande E, Chen A, El-Alfy M, Clermont Y, Seidah N, Chretien M, Gagnon C, Simpson E (1997) Impaired fertility in mice deficient for the testicular germ-cell protease PC4. Proc Natl Acad Sci USA 94:6842–6846
Bassi D, Fu J, Lopez de Cicco R, Klein-Szanto A (2005) Proprotein convertases: “master switches” in the regulation of tumor growth and progression. Mol Carcinog 44:151–161
Stawowy P, Fleck E (2005) Proprotein convertases furin and PC5: targeting atherosclerosis and restenosis at multiple levels. J Mol Med 83:865–875
Panchal M, Rholam M, Brakch N (2004) Abnormalities of peptide metabolism in Alzheimer disease. Curr Neurovasc Res 1:269–281
Zambon MC (2001) The pathogenesis of influenza in humans. Rev Med Virol 11:227–241
Creemers J, Dominguez D, Plets E, Serneels L, Taylor N, Multhaup G, Craessaerts K, Annaert W, De Strooper B (2000) Processing of beta-secretase (Bace) by furin and other members of the proprotein convertase family. J Biol Chem 276:4211–4217
Pinnix I, Council J, Roseberry B, Onstead L, Mallender W, Sucic J, Sambamurti K (2001) Convertases other than furin cleave β-secretase to its mature form. FASEB J 15:1810–1812
Lopez-Perez E, Zhang Y, Frank S, Creemers J, Seidah N, Checler F (2001) Constitutive α-secretase cleavage of the β-amyloid precursor protein in the furin-deficient LoVo cell line: involvement of the prohormone convertase 7 and the disintegrin metalloprotease ADAM-10. J Neurochem 76:1532–1539
Endres K, Anders A, Kojro E, Gilbert S, Fahrenholz F, Postina R (2003) Tumor necrosis factor-α converting enzyme is processed by proprotein-convertases to its mature form which is degraded upon phorbol ester stimulation. Eur J Biochem 270:2386–2393
Hiraoka Y, Ohno M, Yoshida K, Okawa K, Tomimoto H, Kita T, Nishi E (2007) Enhancement of alpha-secretase cleavage of amyloid precursor protein by a metalloendopeptidase nardilysin. J Neurochem 102:1595–1605
Bassi D, Mahloogi H, Al-Saleem L, Lopez de Cicco R, Ridge J, Klein-Szanto A (2001) Elevated furin expression in aggressive human head and neck tumours and tumor cell lines. Mol Carcinog 31:224–232
Leitlein J, Aulwurm S, Waltereit R, Naumann U, Wagenknecht B, Garten W, Weller M, Platten M (2001) Processing of immunosuppressive pro-TGF-beta 1, 2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. J Immunol 166:7238–7243
Siegfried G, Basak A, Cromlish J, Benjannet S, Marcinkiewicz J, Chretien M, Seidah N, Khatib A (2003) The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest 111:1723–1732
Khatib A, Siegfried G, Prat A, Luis J, Chretien M, Metrakos P, Seidah N (2001) Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. J Biol Chem 276:30686–30693
Coppola J, Bhojani M, Ross B, Rehemtulla A (2008) A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia 10:363–370
Gordon V, Klimpel K, Arora N, Henderson M, Leppla S (1995) Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect Immun 63:82–87
Beauregard K, Collier R, Swanson J (2000) Proteolytic activation of receptor-bound anthrax protective antigen on macrophages promotes its internalization. Cell Microbiol 2:251–258
Basak A, Zhong M, Munzer J, Chretien M, Seidah N (2001) Implication of the proprotein convertases furin, PC5 and PC7 in the cleavage of surface glycoproteins of Hong Kong, Ebola and respiratory syncytial viruses: a comparative analysis with fluorogenic peptides. Biochem J 353:537–545
Jean F, Thomas L, Molloy S, Liu G, Jarvis M, Nelson J, Thomas G (2000) A protein-based therapeutic for human cytomegalovirus infection. Proc Natl Acad Sci USA 97:2864–2869
Peinado J, Kacprzak M, Leppla S, Lindberg I (2004) Cross-inhibition between furin and lethal factor inhibitors. Biochem Biophys Res Commun 321:601–605
Shiryaev S, Remacle A, Ratnikov B, Nelson N, Savinov A, Wei G, Bottini M, Rega M, Parent A, Desjardins R, Fugere M, Day R, Sabet M, Pellecchia M, Liddington R, Smith J, Mustelin T, Guiney D, Lebl M, Strongin A (2007) Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem 282:20847–20853
Holyoak T, Wilson M, Fenn T, Kettner C, Petsko G, Fuller R, Ringe D (2003) 2.4 Å resolution crystal structure of the prototypical hormone-processing protease Kex2 in complex with an Ala–Lys–Arg boronic acid inhibitor. Biochemistry 42:6709–6718
Henrich S, Cameron A, Bourenkov G, Kiefersauer R, Huber R, Lindberg I, Bode W, Than M (2003) The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nat Struct Biol 10:520–526
Rockwell N, Thorner J (2004) The kindest cuts of all: crystal structures of Kex2 and furin reveal secrets of precursor processing. Trends Biochem Sci 29:80–87
Sarac M, Cameron A, Lindberg I (2002) The furin inhibitor hexa-d-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo. Infect Immun 70:7136–7139
Kibler K, Miyazato A, Yedavalli V, Dayton A, Jacobs B, Dapolito G, Kim S, Jeang K (2004) Polyarginine inhibits gp160 processing by furin and suppresses productive human immunodeficiency virus type 1 infection. J Biol Chem 279:49055–49063
Fugere M, Day R (2002) Inhibitors of the substilase-like pro-protein convertases (SPCs). Curr Pharm 8:549–562
Jiao G, Cregar L, Wang J, Millis S, Tang C, O’Malley S, Johnson A, Sareth S, Larson J, Thomas G (2006) Synthetic small molecule furin inhibitors derived from 2, 5-dideoxystreptamine. Proc Natl Acad Sci USA 103:19707–19712
Remacle A, Shiryaev S, Oh E, Cieplak P, Srinivasan A, Wei G, Liddington R, Ratnikov B, Parent A, Desjardins R, Day R, Smith J, Lebl M, Strongin A (2008) Substrate cleavage analysis of furin and related proprotein convertases. A comparative study. J Biol Chem 283:20897–20906
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rholam, M., Fahy, C. Processing of peptide and hormone precursors at the dibasic cleavage sites. Cell. Mol. Life Sci. 66, 2075–2091 (2009). https://doi.org/10.1007/s00018-009-0007-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-009-0007-5